3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 2/3
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Prostatic Neoplasms
3
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Stomach Neoplasms
1
Pancreatic Adenocarcinoma
1
Pain
1
Neoplasm Metastasis
1
NSCLC
1
Lymphatic Metastasis
1
Colorectal Neoplasms
1
Castration-resistant Prostate Cancer Patients with Oligometastases
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Pemetrexed
2
Gefitinib
2
spartalizumab
1
aflutinib
1
Tyrosine Kinase Inhibitors
1
Thalidomide
1
Radiosurgery
1
Platinum
1
Immune Checkpoint Inhibitors
1
Drug Therapy
1
Axitinib
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
NSCLC
×
Radiosurgery
×
Clear all
NCT03256981
2023-12-26
HALT
Institute of Cancer Research, United Kingdom
Phase 2/3
Unknown
113 enrolled